Ophthalmic Disorders

Ryzumvi is a preservative-free eye drop formulation of phentolamine mesylate, a nonselective alpha-1 and alpha-2 adrenergic antagonist that reduces pupil size.

FDA withdraw multiple myeloma treatment after a confirmatory trial showed an increased risk of death; latest efficacy results for Abrysvo vaccine; chikungunya virus vaccine recommendations; Complete Response Letter issued to investigative schizophrenia treatment; new treatment for complicated UTIs including pyelonephritis; over-the-counter eye ointments recalled.

Simlandi is an interchangeable biosimilar and can be substituted for the reference product without requiring a prescription change.

Biogen discontinue Alzheimer treatment; The American Academy of Dermatology issue new acne vulgaris management guidelines; Update for ongoing Paxlovid availability; Narcolepsy/ADHD treatment recalled; FDA warn against copycat eye drop products.

South Moon, Rebright, or FivFivGo eye drops are unapproved drugs with claims to treat eye conditions such as glaucoma.

Vevye is supplied in a 5mL multiple-dose eye drop bottle containing 2mL of solution.

The US Food and Drug Administration (FDA) approved a wide range of therapies in 2023, including many new molecular entities and biological products. The information below is organized by the month in which the product received approval. 

Sodium-glucose co-transporter 2 inhibitor use was associated with significantly lower risks for diabetic retinopathy compared with the use of dipeptidyl peptidase-4 inhibitors, sulfonylureas, and pioglitazone.

The table below is a review of notable updates that occurred in November 2023 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.